PharmAla Expands MDMA Trial Footprint With Nautilus Sanctuary Data Deal

PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has shared an announcement.

PharmAla Biotech has signed a Supply & Data Agreement with Nautilus Sanctuary in New York to provide its LaNeo MDMA for a Phase 2 open-label clinical trial using MDMA-assisted therapy to treat post-traumatic stress and adjustment disorders in frontline healthcare workers and first responders. In exchange for donating the drug, PharmAla receives a perpetual, non-exclusive license to de-identified trial data for global regulatory and commercial use, reinforcing its supply-for-data model and expanding its evidence base for LaNeo MDMA, while also completing a separate LaNeo MDMA shipment to University College London for another clinical study.

The Nautilus trial underscores PharmAla’s strategy of supporting high-need mental health populations while building a robust portfolio of clinical data to cement its position as a key supplier of clinical-grade MDMA. By deepening its involvement in U.S. and U.K. research, the company strengthens its industry positioning in psychedelic-assisted therapies, potentially benefiting regulators, clinicians, and patients through accelerated evidence generation on MDMA’s safety and efficacy.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.09 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

Spark’s Take on TSE:MDMA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.

The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.

To see Spark’s full report on TSE:MDMA stock, click here.

More about PharmAla Biotech Holdings, Inc.

PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development, and manufacturing of MDXX-class molecules, including MDMA. The company focuses on alleviating the global backlog of clinical-grade MDMA for trials and select commercial uses, while also advancing novel psychedelic drug candidates through a regulatory-first, cGMP-compliant value chain in North America.

Average Trading Volume: 128,513

Technical Sentiment Signal: Sell

Current Market Cap: C$10.34M

Find detailed analytics on MDMA stock on TipRanks’ Stock Analysis page.